Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

NovoCure Limited (NVCR)

16.15   -0.48 (-2.89%) 09-29 16:00
Open: 16.65 Pre. Close: 16.63
High: 16.79 Low: 16.06
Volume: 1,425,775 Market Cap: 1,722(M)

Technical analysis

as of: 2023-09-29 4:29:21 PM
Short-term rate:       
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Mid-term rate:       
Target: Six months: 29.05     One year: 35.42
Support: Support1: 16.05    Support2: 13.36
Resistance: Resistance1: 24.87    Resistance2: 30.32
Pivot: 18.22
Moving Average: MA(5): 16.87     MA(20): 18.89
MA(100): 40.6     MA(250): 61.44
MACD: MACD(12,26): -2.8     Signal(9): -3.1
Stochastic oscillator: %K(14,3): 3.1     %D(3): 5.8
RSI: RSI(14): 18.9
52-week: High: 120.02  Low: 16.05
Average Vol(K): 3-Month: 1,868 (K)  10-Days: 1,456 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NVCR ] has closed above bottom band by 10.5%. Bollinger Bands are 69.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 16.9 - 17.06 17.06 - 17.16
Low: 15.72 - 15.93 15.93 - 16.06
Close: 15.91 - 16.25 16.25 - 16.45

Company Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Headline News

Fri, 29 Sep 2023
Novocure Announces Presence at American Society for Radiation ... -

Fri, 22 Sep 2023
Is Novocure Ltd (NVCR) Stock About to Get Hot Friday? - InvestorsObserver

Thu, 21 Sep 2023
Macquarie Group Ltd. Decreases Stock Position in NovoCure ... - MarketBeat

Mon, 18 Sep 2023
Should You Hold NovoCure Limited (NVCR)? - Yahoo Finance

Wed, 06 Sep 2023
Korea Investment CORP Decreases Stake in NovoCure Limited ... - Best Stocks

Sat, 02 Sep 2023
Lifshitz Law PLLC Announces Investigations of Peloton Interactive ... - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Instruments & Supplies
Shares Out. 107 (M)
Shares Float 95 (M)
% Held by Insiders 1.2 (%)
% Held by Institutions 85.5 (%)
Shares Short 9,210 (K)
Shares Short P.Month 8,860 (K)

Stock Financials

EPS -1.63
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.9
Profit Margin (%) -34.4
Operating Margin (%) -37.5
Return on Assets (ttm) -10.3
Return on Equity (ttm) -40.7
Qtrly Rev. Growth -10.5
Gross Profit (p.s.) 3.97
Sales Per Share 4.76
EBITDA (p.s.) -1.69
Qtrly Earnings Growth 0
Operating Cash Flow -21 (M)
Levered Free Cash Flow 141 (M)

Stock Valuations

PE Ratio -9.91
PEG Ratio -0.2
Price to Book value 4.14
Price to Sales 3.39
Price to Cash Flow -82.99

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.